Harrow, Inc. (NASDAQ:HROW) Shares Purchased by Trexquant Investment LP

Trexquant Investment LP boosted its position in shares of Harrow, Inc. (NASDAQ:HROW) by 1,806.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 94,500 shares of the company’s stock after purchasing an additional 89,544 shares during the quarter. Trexquant Investment LP’s holdings in Harrow were worth $3,170,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in shares of Harrow by 443.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock worth $10,717,000 after purchasing an additional 194,480 shares in the last quarter. Barclays PLC increased its position in Harrow by 301.9% during the third quarter. Barclays PLC now owns 52,593 shares of the company’s stock worth $2,365,000 after buying an additional 39,506 shares in the last quarter. State Street Corp raised its holdings in shares of Harrow by 2.2% in the third quarter. State Street Corp now owns 730,973 shares of the company’s stock worth $32,865,000 after acquiring an additional 15,554 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Harrow by 195.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after acquiring an additional 166,602 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Harrow during the third quarter valued at $1,469,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Stock Performance

Shares of Harrow stock opened at $23.52 on Monday. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. Harrow, Inc. has a 1 year low of $9.86 and a 1 year high of $59.23. The firm’s 50-day simple moving average is $27.98 and its 200-day simple moving average is $37.30. The firm has a market cap of $838.58 million, a PE ratio of -25.02 and a beta of 0.46.

Harrow (NASDAQ:HROW) last issued its earnings results on Thursday, March 27th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The company had revenue of $66.83 million for the quarter, compared to analysts’ expectations of $66.01 million. Equities analysts forecast that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HROW has been the topic of several recent analyst reports. B. Riley reduced their price objective on shares of Harrow from $69.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Harrow in a research note on Monday, March 31st.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.